☆ 4.2 Article

Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody

TRANSFUSION (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Antibody incidence and red blood cell transfusions in patients on daratumumab

Craig Tauscher et al.

Summary: The study aimed to evaluate RBC utilization and alloimmunization in patients receiving Dara, showing that these patients did not have a higher incidence of alloantibody formation following RBC transfusion compared to similar patient populations.

TRANSFUSION (2021)

Add to Collection

Article Hematology

Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens

Samantha Phou et al.

Summary: This study reviewed patients receiving daratumumab treatment and found a low incidence of alloimmunization, suggesting that only ABO-compatible units prophylactically matched for the D and K antigens are necessary for transfusion.

TRANSFUSION (2021)

Add to Collection

Article Hematology

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Elisabeth Ehrend et al.

BLOOD (2021)

Add to Collection

Article Hematology

Use of an in-house trypsin-based method to resolve the interference of daratumumab

Nnaemeka Ibeh et al.

Summary: A trypsin-based method was demonstrated to effectively remove DARA interference in antibody testing, with successful identification of known alloantibodies and no false-negative results. This method provides a safe and cost-effective option for pretransfusion testing in patients receiving DARA.

TRANSFUSION (2021)

Add to Collection

Review Hematology

Daratumumab: Beyond Multiple Myeloma

Kiran Ejaz et al.

Summary: Daratumumab is a human monoclonal antibody targeting CD38 expressing-plasma cells, approved for the treatment of multiple myeloma and being investigated for other hematologic malignancies. It has potential applications in treating various antibody-mediated disorders beyond its current approved uses.

TRANSFUSION MEDICINE REVIEWS (2021)

Add to Collection

Review Hematology

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

Marilyn T. Nedumcheril et al.

Summary: Daratumumab, a monoclonal antibody therapeutic, is highly effective in treating multiple myeloma and amyloidosis, but can interfere with pre-transfusion testing. Various methods have been developed to address this interference, requiring coordination between blood bank and clinical teams for implementation. Efforts to improve daratumumab safety in blood transfusions include timely involvement of transfusion services and educational efforts by both blood banks and clinical providers.

JOURNAL OF BLOOD MEDICINE (2021)

Add to Collection

Article Hematology

Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing

Tony Tremblay et al.

TRANSFUSION (2020)

Add to Collection

Article Hematology

A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing

Karen N. Chinoca Ziza et al.

TRANSFUSION (2019)

Add to Collection

Review Oncology

Daratumumab in multiple myeloma

Ajay K. Nooka et al.

CANCER (2019)

Add to Collection

Letter Hematology

Additional validation of Osaka method (0.01 mol/L dithiothreitol) for negating the daratumumab interference

Mika Hosokawa et al.

TRANSFUSION (2019)

Add to Collection

Letter Hematology

Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma

Tsung-Jang Yeh et al.

TRANSFUSION (2019)

Add to Collection

Article Oncology

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma

Ajai Chari et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)

Add to Collection

Article Medicine, General & Internal

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Hang Quach et al.

INTERNAL MEDICINE JOURNAL (2018)

Add to Collection

Letter Medicine, General & Internal

F(ab′)2 Fragments to Overcome Daratumumab Interference in Transfusion Tests

Kathleen Selleng et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method)

Mika Hosokawa et al.

TRANSFUSION (2018)

Add to Collection

Article Hematology

Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy

Waseem Q. Anani et al.

TRANSFUSION (2017)

Add to Collection

Letter Medicine, General & Internal

Daratumumab and Blood-Compatibility Testing

Jose-Luis Bueno et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Hematology

International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing

Claudia I. Chapuy et al.

TRANSFUSION (2016)

Add to Collection

Letter Hematology

Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma

Judith L. Hannon et al.

TRANSFUSION (2015)

Add to Collection

Letter Hematology

An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab

Amy E. Schmidt et al.

TRANSFUSION (2015)

Add to Collection

Article Hematology

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

Marlies Oostendorp et al.

TRANSFUSION (2015)

Add to Collection

Article Hematology

Resolving the daratumumab interference with blood compatibility testing

Claudia I. Chapuy et al.

TRANSFUSION (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.